By Steve Kardell | Published November 16, 2017 | Posted in Whistleblower Litigation | Tagged Tags: Celgene Corporation, provided sufficient evidence, Thalomid and Fevlimid |
Celgene Corporation, a biotech company based in New Jersey, will pay out $280 million to settle claims that it cited uses not approved by the U.S. Food and Drug Administration (FDA) in promotion of its cancer treatment drugs Thalomid and Fevlimid. According to Judge George H. King, the plaintiff “provided sufficient evidence” that the corporation Read More
Read More